Immunome (NASDAQ:IMNM) Hits New 12-Month Low - Time to Sell?

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as $5.43 and last traded at $5.79, with a volume of 240742 shares. The stock had previously closed at $5.93.

Wall Street Analyst Weigh In

IMNM has been the topic of several recent analyst reports. Stephens reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Guggenheim lowered their price target on Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, March 20th. Lake Street Capital started coverage on Immunome in a report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price objective on the stock. Wedbush reiterated an "outperform" rating and issued a $33.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Lifesci Capital began coverage on Immunome in a research report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $25.14.

Immunome Stock Performance

The firm has a market capitalization of $617.35 million, a PE ratio of -0.88 and a beta of 2.05. The stock has a fifty day moving average price of $8.56 and a 200-day moving average price of $10.60.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million during the quarter, compared to analysts' expectations of $3.07 million. Research analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Activity at Immunome

In other Immunome news, CTO Philip Tsai bought 12,300 shares of Immunome stock in a transaction that occurred on Monday, March 24th. The shares were bought at an average cost of $8.42 per share, with a total value of $103,566.00. Following the transaction, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at approximately $280,386. This represents a 58.57 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall purchased 137,100 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $7.29 per share, with a total value of $999,459.00. Following the completion of the purchase, the chief executive officer now owns 806,736 shares of the company's stock, valued at $5,881,105.44. The trade was a 20.47 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 306,400 shares of company stock valued at $2,322,995 over the last 90 days. Insiders own 8.60% of the company's stock.

Hedge Funds Weigh In On Immunome

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in Immunome in the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome during the fourth quarter worth $75,000. AlphaQuest LLC grew its holdings in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in Immunome in the 4th quarter worth $95,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.